06
08 '16
The Food and Drug Administration (FDA) has approved changes to the drug labeling for fluoroquinolone antibacterials for systemic use. This class of drugs has been associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system (CNS) that can simultaneously occur in the patient. Currently available fluoroquinolones include:…
